Usted buscó: phvwp (Finés - Inglés)

lääketurvatoimintatyöryhmä (phvwp)
pharmacovigilance working party (phvwp)

cpmp/ phvwp/ 175/ 95
cpmp/phvwp/175/95

lääketurvatoiminnan työryhmä (phvwp)
6

emea/ cpmp/ phvwp/ 2058/ 99
emea/cpmp/phvwp/2058/99

viitenumero cpmp/ phvwp/ 1618/ 01
cpmp/phvwp/1618/01

emea/ cpmp/ ewp/ phvwp / 1417/ 01
emea/cpmp/ewp/phvwp/ 1417/01

cpmp: n lääkevalvonnan työryhmä viitenumero cpmp/ phvwp/ 4838/ 02
cpmp pharmacovigilance working party

emea/ cpmp/ bpwg/ 1561/ 99 emea/ cpmp/ phvwp/ bpwg /
emea/cpmp/bpwg/ 1561/99

lääkevalvontatyöryhmä (phvwp) , jonka puheenjohtajana oli tri susan wood (), kokoontui seitsemän kertaa vuonna 1998.
the pharmacovigilance working party (phvwp) chaired by dr susan wood () held seven meetings in 1998.

johtopäätöksissään chmp vahvisti harmonisoidun sanamuodon lääketurvatyöryhmän (phvwp) ace: n estäjien raskaudenaikaista käyttöä koskevan sanamuodon mukaisesti.
in conclusions, the chmp adopted a harmonised wording in line with phvwp wording on use of aec-i in pregnancy.

joint phvwp/ ewp concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy: need for post- marketing data
joint phvwp/ewp concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy: need for post-marketing data

1 administration (ivig) core spc for human plasma derived and emea/cpmp/bpwg/1619/99 recombinant coagulation factor viii hyväksytty kesäkuussa 2000 products core spc for human plasma derived and emea/cpmp/bpwg/1625/99 hyväksytty kesäkuussa 2000 recombinant coagulation factor ix products note for guidance on the clinical emea/cpmp/bpwg/198/95 rev. 1 investigation of human plasma derived hyväksytty lokakuussa 2000 factor viii and ix products note for guidance on the clinical emea/cpmp/bpwg/1561/99 investigation of recombinant factor viii hyväksytty lokakuussa 2000 and ix products emea/cpmp/phvwp/bpwg/core spc for human albumin hyväksytty lokakuussa 2000 2231/99
emea/cpmp/bpwg/1561/99emea/cpmp/phvwp/bpwg/2231/99 emea/cpmp/bpwg/2220/99emea/cpmp/bpwg/3226/99cpmp efficacy working party reference number emea/cpmp/ewp/519/98 emea/cpmp/ewp/197/99emea/cpmp/ewp/570/98emea/cpmp/ewp/2922/99emea/cpmp/ewp/2863/99emea/cpmp/ewp/707/98emea/cpmp/ewp/612/00emea/cpmp/ewp/2655/99emea/cpmp/ewp/482/99 emea/cpmp/ewp/1080/00emea/cpmp/ewp/565/98emea/cpmp/ewp/785/97emea/cpmp/ewp/566/98 rev.1emea/cpmp/ewp/2284/99emea general report 2000core spc for human albumin adopted october 2000 note for guidance on the clinical investigation of human plasma derived factor viii and ix products released for consultation june 2000 note for guidance on the clinical investigation of recombinant factor viii and ix products released for consultation june 2000 core spc for human albumin released for consultation june 2000 note for guidance on the clinical investigation of plasma derived antithrombin products released for consultation december 2000 core spc for human plasma derived antithrombin released for consultation december 2000